This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
EyeTech Pharmaceuticals Inc. (eye disease drugs) could raise as much as $108.5mm in a two-tranche private placement of Series C preferred stock led by JP Morgan Partners. Other investors were BB Biotech, MPM Capital, Alta Partners, Schroder Ventures, and Merrill Lynch. The first half of the financing is payable immediately; the second $54.2mm is payable on the completion of enrollment of the two pivotal Phase III trials of its lead product, Macugen, for age-related macular degeneration (AMD).
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?